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OBJECTIVE: Anaplastic thyroid carcinoma arises from differentiated carcinoma and has a very aggressive
character. In this study, we investigated the prognosis of patients with anaplastic carcinoma based on
UICC stage.
PATIENTS AND METHODS: We investigated the prognosis of 75 patients who were diagnosed as having
anaplastic carcinoma at Kuma Hospital between 1983 and 2006. Of these patients, 14, 49 and 12 were
classified into Stages IVA, IVB, and IVC respectively.
RESULTS: Stage IVA patients showed a significantly better prognosis than Stage IVB or IVC patients
(p = 0.0017). All patients with Stage IVC died of carcinoma within 1 year regardless of whether locally
complete resection was performed. Prognosis of Stage IVB patients who underwent curative surgery did
not differ from that of Stage IVA patients, but the prognosis of those who did not undergo surgery or
only received palliative surgery was as poor as that of Stage IVC patients.
CONCLUSIONS: Extensive surgical treatment is recommended for Stage IVA patients and palliative
care is appropriate for Stage IVC patients. For Stage IVB patients, surgical treatment as a primary therapy is
appropriate only when curative resection of the tumour is expected. [Asian J Surg 2009;32(1):47–50]
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Introduction
Thyroid carcinoma is a representative malignancy origi-
nating from the endocrine organs. The two kinds of car-
cinoma arising from thyroid follicular cells are papillary
and follicular carcinomas, which are also called differen-
tiated carcinoma and generally have a mild biological
characteristic. However, when these lesions dedifferenti-
ate and become anaplastic (undifferentiated), patients
show a far more adverse prognosis than those with differ-
entiated carcinoma. Although this event is uncommon,
and previous studies have shown some prognostic factors
of anaplastic carcinoma,1–6 long-term survival could not
be expected for most patients with undifferentiated car-
cinoma even if they underwent multimodal therapy, 
combining surgery, chemotherapy and radiotherapy.7,8
Furthermore, a previous study demonstrated that cura-
tive resection is the strongest prognostic factor for this
carcinoma.9
To evaluate the biological characteristics of thyroid
carcinoma, several staging systems have been published
and the UICC stage grouping is the most widely accepted.
This system was revised in 2002 (6th edition),10 and we
previously demonstrated that T4 and N1b, which are
components of Stage IV for patients aged 45 years or older,
independently affected both disease-free survival (DFS)
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and cause-specific survival (CSS) of patients with papillary
carcinoma.11 Stage grouping for anaplastic carcinoma
was also revised at the same time. All anaplastic carcino-
mas were classified into Stage IV, which is further divided
into three subcategories; Stage IVA, tumour limited to the
thyroid; Stage IVB, tumour beyond the thyroid capsule;
and Stage IVC, presence of distant metastasis. In this study,
we investigated the prognosis of patients with anaplastic
carcinoma treated at our institute and evaluated appro-
priate therapeutic strategies for patients at each stage.
Patients and methods
Seventy-five patients, who were diagnosed as having
anaplastic carcinoma by cytological and/or pathological
examinations in Kuma Hospital and treated in Kuma
Hospital or associated hospitals between 1983 and 2006,
were enrolled in this study. Specimens from all of these
cases were re-examined by a coauthor (M.H.) and con-
firmed as anaplastic carcinoma. These patients consisted
of 65 females and 10 males and the average patient age
was 66.9 years. Patients with anaplastic transformation of
recurrent tumours following surgery for differentiated
carcinoma and those with anaplastic carcinoma detectable
only in the lymph node but not in the primary tumour
were excluded from this series. Follow-up periods after
diagnosis ranged from 1 to 212 months and averaged 13.5
months. Surgical treatment was performed for 57 patients.
Twenty-nine of these patients underwent curative surgery
and the remaining 28 underwent palliative surgery only. The
ranges of thyroidectomy for 29 patients who underwent
curative surgery were total thyroidectomy in 18 patients,
subtotal thyroidectomy in six patients, and lobectomy in
five patients. Lymph node dissection was performed for
27 of these patients. Six patients underwent bilateral modi-
fied radical neck dissection (MND), 20 underwent unilat-
eral MND. The range of dissection is unknown for the
remaining one patient who underwent surgery at another
hospital. Three patients also underwent dissection of the
mediastinal lymph nodes. Forty patients (53.3%) under-
went radiotherapy and 36 patients (48.0%) underwent
chemotherapy. Twenty-four of these patients underwent
both therapies. Three patients underwent radiotherapy as
a primary therapy and two of these patients did not
undergo surgical treatment. Twelve patients underwent
chemotherapy as a primary therapy and four of these
patients underwent surgical treatment thereafter.
Grading of UICC stage grouping
All patients were graded based on the UICC stage at the
time of diagnosis.3 Extracapsular extension was diagnosed
by palpation and various imaging studies such as ultra-
sonography and computed tomography (CT) scan. Distant
metastasis was also diagnosed by imaging studies.
Statistical analyses
Fisher’s exact test was used for the analysis of variables.
The Kaplan-Meier method and log rank test were adopted
to analyse time-dependent variables. These analyses were
performed using StatView-J 5.0. A p value less than 0.05
was regarded as significant.
Results
We classified 75 patients with anaplastic carcinoma based
on UICC stage. Of these patients, 14, 49, and 12 were clas-
sified into Stages IVA, IVB, and IVC, respectively. All Stage
IVA patients underwent curative resection of the tumour.
Adjuvant therapy was performed for 11 patients. Eleven
patients underwent chemotherapy and eight underwent
radiotherapy. Eight of these patients underwent both ther-
apies. Stage IVA patients showed a significantly better
CSS than those in Stage IVB or IVC (p = 0.0017) as shown
in Figure 1. Six patients with Stage IVA were alive 1 year
later, and four were alive longer than 5 years after diagno-
sis. One patient was confirmed alive more than 17 years
(212 months) after diagnosis. All patients with Stage IVC
died of carcinoma within 1 year regardless of whether
locally complete resection was performed.
Of patients with Stage IVB, curative resection was
achieved based on intra-operative findings in 15 patients.
Thirteen of these patients underwent adjuvant therapy;
11 of these thirteen underwent radiotherapy and ten of
the thirteen underwent chemotherapy. Eight patients
underwent both therapies. One patient underwent pacli-
taxel administration as a primary therapy12 and underwent
curative resection after tumour shrinkage. As shown in
Figure 2, prognosis of these patients did not differ from
that of those with Stage IVA. Of the remaining 34 patients
who did not undergo surgery or underwent only palliative
surgery. Of these 34, 19 underwent chemotherapy and/or
radiotherapy. Amongst these 19, chemotherapy and radio-
therapy were performed for 11 patients and 14 patients,
respectively, and six underwent both of them. However 
all patients died of carcinoma within 18 months after
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diagnosis. Their prognoses were as poor as that of those
with Stage IVC (Figure 3).
Figure 4 summarises the CSS of patients belonging to
the four categories; Stage IVA, Stage IVB with curative
surgery, Stage IVB with no or only palliative surgery, and
Stage IVC. In total, five patients (four with Stage IVA and
one with Stage IVB with curative surgery) survived longer
than 5 years. There were no special pathological findings
in these patients. All patients except for one with Stage
IVA underwent radiotherapy and chemotherapy.
Discussion
In this study, we focused on the prognosis of anaplastic
carcinoma patients at each UICC stage. Since tumours of
Stage IVA patients do not extend to adjacent organs or show
distant metastasis, it is reasonable to expect long-term
survival after curative resection. Therefore, extensive sur-
gical treatment can be the first line of therapy. Recently,
radiotherapy and chemotherapy have been adopted as
effective adjuvant therapies for anaplastic carcinoma.13–16
Also in our series, four of the five patients who survived
more than 5 years underwent radiotherapy and chemother-
apy, indicating the possibility that these therapies after
curative surgery can further prolong patient survival.
However, none of the patients having distant metastasis
survived for more than 1 year, even if locally curative sur-
gery was performed, indicating that surgical treatment
has no survival benefit for Stage IVC patients. Therefore,
palliative care should be considered the most appropriate
for these patients.
In contrast to the prognosis of patients with Stages
IVA and IVC, that of those with Stage IVB was polarised.
Patients whose tumours were curatively resected based on
intra-operative findings have a chance for long-term sur-
vival and their prognoses did not differ from those of
patients in Stage IVA. However, patients who did not
undergo surgery or underwent only palliative surgery could
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Figure 1. Comparison of CSS among anaplastic carcinoma
patients with Stages IVA, IVB, and IVC.
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Figure 2. Comparison of CSS between Stage IVA patients and
Stage IVB patients with curative surgery.
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Figure 3. Comparison of CSS between Stage IVB patients with-
out surgery or with palliative surgery only and Stage IVC patients.
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Figure 4. Comparison of CSS among patients with Stage IVA,
Stage IVB with curative surgery, Stage IVB without surgery or
with palliative surgery only and Stage IVC.
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not survive longer than 18 months and their prognosis
was as poor as that of those with stage IVC. In our series,
debulking surgery did not contribute to prolonged survival
for these patients, which is discrepant with the findings
reported by Sugino et al.17 However, that study excluded
patients who developed novel distant metastasis during
treatment and did not consider whether the primary
tumours showed extrathyroid extension. Differences in
patient background between their series and ours may be
one reason for discrepancies among these data. The only
advantage of debulking surgery may be to facilitate tra-
cheostomy in order to prevent airway obstruction. Since
stage grouping is based on pre-operative evaluation, further
segmentation of Stage IVB should be difficult.
Intra-operative findings are the most important to
predict the prognosis of patients classified as Stage IVB
preoperatively. The therapeutic strategies of Stage IVB
patients in whom curative surgery is expected can be the
same as those of Stage IVA patients, that is, extensive sur-
gical treatment followed by radiotherapy and chemother-
apy. For Stage IVB patients in whom curative surgery
cannot be expected, primary chemotherapy and radio-
therapy for tumour shrinkage may be more appropriate
as demonstrated by Besic et al.18 If tumour shrinkage
allows the possibility of curative surgery, surgical treat-
ment can be performed as a second line. Otherwise, long-
term survival cannot be expected for these patients.
In this study, we recommended appropriate strategies
for anaplastic carcinoma patients based on UICC staging
system. Curative surgery and palliative care are recom-
mended for patients with Stages IVA and IVC, respec-
tively. However, therapeutic strategies for Stage IVB patients
are polarised depending on whether curative surgery can
be expected.
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